Cargando…

A review of ocular adverse events of biological anti-TNF drugs

The recent introduction of biological agents has revolutionized the treatment of chronic immune-inflammatory diseases; however, this new therapy did not come without significant side effects. Through large controlled studies indicating decrease in the number of uveitis flares, the role of TNF inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicolela Susanna, Fernanda, Pavesio, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184065/ https://www.ncbi.nlm.nih.gov/pubmed/32337619 http://dx.doi.org/10.1186/s12348-020-00202-6

Ejemplares similares

Peak Intraocular Pressure Time during Water Drinking Test and Its Relationship with Glaucoma Severity
por: Susanna, Carolina Nicolela, et al.
Publicado: (2022)

Adverse events of antibody–drug conjugates on the ocular surface in cancer therapy
por: Domínguez-Llamas, Sandra, et al.
Publicado: (2023)

Ocular adverse effects of therapeutic biologics
por: Neves da Silva, Helio V., et al.
Publicado: (2022)

Ocular inflammatory events following COVID-19 vaccination: a multinational case series
por: Testi, Ilaria, et al.
Publicado: (2022)

Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
por: Martens, A., et al.
Publicado: (2023)

Ocular sarcoidosis in adults and children: update on clinical manifestation and diagnosis
por: Bazewicz, Magdalena, et al.
Publicado: (2023)

Assessment and monitoring of biologic drug adverse events in patients with psoriasis
por: Hanley, Tessa, et al.
Publicado: (2016)

Ocular adverse effects of anti-cancer chemotherapy
por: Stoicescu, Elena Andreea, et al.
Publicado: (2023)

Ocular tuberculosis: Where are we today?
por: Testi, Ilaria, et al.
Publicado: (2020)

Common Adverse Effects of Anti-TNF Agents on Gestation
por: Fasoulakis, Zacharias, et al.
Publicado: (2016)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Adverse events during anti-TNF therapy in 269 patients with juvenile idiopathic arthritis
por: Tarkiainen, M, et al.
Publicado: (2008)

PReS-FINAL-2002: Adverse events during anti-TNF therapy in patients with JIA
por: Tarkiainen, M, et al.
Publicado: (2013)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Retrospective analysis of ocular adverse events with Clobetasol
por: Wang, Yu, et al.
Publicado: (2022)

TNF-α/anti-TNF-α drugs and its effect on pregnancy outcomes
por: Dai, Fang-fang, et al.
Publicado: (2022)

An anti-TNF-α antibody mimetic to treat ocular inflammation
por: Khalili, Hanieh, et al.
Publicado: (2016)

Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study
por: Kaltsonoudis, Evripidis, et al.
Publicado: (2014)

Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis
por: Li, Ju, et al.
Publicado: (2021)

The ocular adverse effects of oral drugs
por: Ahmad, Rawan, et al.
Publicado: (2021)

Anti-TNF-α and hydralazine drug-induced lupus
por: Quaresma, Maria Victória, et al.
Publicado: (2015)

Complications and adverse events of plaque brachytherapy for ocular melanoma
por: Peddada, Krishi V., et al.
Publicado: (2019)

Adverse Ocular Events following COVID-19 Vaccination
por: Eleiwa, Taher K., et al.
Publicado: (2021)

Ocular adverse events from pharmacological treatment in patients with multiple sclerosis—A systematic review of the literature
por: Muñoz-Ortiz, Juliana, et al.
Publicado: (2021)

Recurrence rates in ocular non-infectious uveitis according to US FDA criteria or Rest of World criteria
por: Jaffe, Glenn J., et al.
Publicado: (2022)

TNF-Related Apoptosis Inducing Ligand in Ocular Cancers and Ocular Diabetic Complications
por: Perri, Paolo, et al.
Publicado: (2015)

A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy
por: Parisi, Rose, et al.
Publicado: (2023)

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology
por: Formica, María L., et al.
Publicado: (2021)

Adverse events of vaccines and the consequences of non-vaccination: a critical review
por: Aps, Luana Raposo de Melo Moraes, et al.
Publicado: (2018)

Demyelinating Neurological Adverse Events following the Use of Anti-TNF-α Agents: A Double-Edged Sword
por: Gharib, Miral H., et al.
Publicado: (2022)

Monitoring of anti-TNF biological treatments
por: Ruiz del Agua, A, et al.
Publicado: (2010)

Action after Adverse Events in Healthcare: An Integrative Literature Review
por: Liukka, Mari, et al.
Publicado: (2020)

Biological Treatments in Behçet's Disease: Beyond Anti-TNF Therapy
por: Caso, Francesco, et al.
Publicado: (2014)

Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy
por: Leone, Gian Marco, et al.
Publicado: (2023)

A systematic review of adult admissions to ICUs related to adverse drug events
por: Jolivot, Pierre-Alain, et al.
Publicado: (2014)

The ocular adverse effects of oral drugs [Correction]
Publicado: (2021)

Ocular Adverse Events after Inactivated COVID-19 Vaccination
por: Li, Zhihua, et al.
Publicado: (2022)

Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy
por: Reiss, Zuzana, et al.
Publicado: (2023)

Adverse effects of biologic anti-inflammatory agents on the respiratory system: A review
por: Joseph, D, et al.
Publicado: (2021)

Presumed ocular tuberculosis in the United Kingdom: a British Ophthalmological Surveillance Unit (BOSU) study
por: Shirley, Katherine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1n7utugg0p04tf506t2jjjh9r8